Introduction {#S10}
============

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has become a global health crisis since it was first reported in Wuhan, China, in December 2019.^[@R1]^ COVID-19 has so far caused over 400,000 deaths globally and has spread to the majority of countries around the world.^[@R2]^ New York City is a global epicenter for the SARS-CoV-2 outbreak and a significant number of individuals have been infected by the virus, including both patients with underlying health conditions as well as healthy individuals.^[@R3]^ Clinical symptoms of COVID-19 include fever, cough, fatigue, diarrhea, headaches, and shortness of breath.^[@R1]^ They range from mild symptoms to severe disease characterized by pneumonia, hypoxia, respiratory failure, acute respiratory disease syndrome (ARDS), immune dysregulation, cytokine storm, thromboembolic events, and multiorgan failure.^[@R1]^ Reported risk factors for severe COVID-19 disease are male gender, advanced age, smoking, and certain comorbidities such as hypertension.^[@R1],[@R4]^

Five studies of varying size have suggested that patients with cancer on active therapy or recent surgery had a higher risk of a more severe COVID-19 disease course.^[@R5]--[@R9]^ Additionally, recent immunotherapy treatment with checkpoint inhibitors was associated with a poorer outcome.^[@R7]^ Patients with multiple myeloma have an inherently compromised humoral and cellular immunity from the malignant plasma cell disorder itself and its associated hypogammaglobulinemia.^[@R10]^ The immunosuppression seen at presentation can be exacerbated by the standard combination anti-myeloma therapies currently in use.^[@R11]^ Among the conventional treatment options for multiple myeloma, the use of high-dose melphalan chemotherapy followed by autologous stem cell transplant is particularly associated with acute and sustained hypogammaglobulinemia and T-cell suppression.^[@R12]^ Here, we report on the largest experience to date from a cohort of multiple myeloma patients with COVID-19 from five large academic centers in New York City.

Methods {#S11}
=======

Consecutive patients with multiple myeloma and related precursor diseases, hospitalized as well as outpatients, were included in this study. Participating centers are: Memorial Sloan Kettering Cancer Center (N=52), New York University Langone Health (N=30), Mount Sinai (N=23), Weill Cornell Medicine (N=13), and Columbia University Medical Center (N=9). The presence of SARS-CoV-2 was confirmed using real time polymerase chain reaction through nasopharynx swab. Patients with confirmed COVID-19 during the peak of the outbreak between March 10^th^ and April 30^th^, 2020 were included in this cohort study.

We obtained data on patient characteristics, comorbidities, laboratory findings, treatments, and outcomes. In addition to descriptive statistics, logistic regression was used to estimate risk factors associated with adverse outcomes. Taking this approach, we estimated odds ratios (ORs) with 95% confidence intervals (CIs). The primary composite end-point was admission to an intensive care unit (ICU), need for mechanical ventilation, or death. Hypogammaglobulinemia was defined as immunoglobulin G (IgG) levels \<650 mg/dL (lower limit of normal), and severe hypogammaglobulinemia was defined as IgG levels \<400 mg/dL. Separate analyses were performed for patients with multiple myeloma (N=100) and for all patients with plasma cell disorders (N=127).

Results {#S12}
=======

We identified a total of 100 patients with multiple myeloma and COVID-19. Median age at the time of COVID-19 infection was 68 years (range 41--91 years). Fifty-eight (58%) of the patients were male and 24 were current or former smokers ([Table 1](#T1){ref-type="table"}). Concomitant cardiovascular or pulmonary comorbidities were seen in 74 patients of which hypertension was the most common (56%). Additionally, 27 patients with related plasma cell disorders; 20 with monoclonal gammopathy of undetermined significance (MGUS) and 3 with smoldering multiple myeloma (SMM), 3 patients with AL amyloidosis, and 1 patient with solitary plasmacytoma, were identified ([Table 1](#T1){ref-type="table"}).

Of the 100 patients with multiple myeloma, 28 patients (28%) had newly diagnosed multiple myeloma; 26 were being treated with induction therapy, one had not yet started induction and one had chosen not to start therapy. There were 35 (35%) patients with stable disease (i.e. non-active disease); 23 of these were on lenalidomide maintenance, 5 were on other forms of maintenance including ixazomib/dexamethasone and daratumumab/dexamethasone and 7 patients with stable disease were monitored off therapy. Thirty-five (35%) patients had relapse/refractory multiple myeloma of which 31 were on various treatments for relapsed/refractory multiple myeloma; the majority daratumumab- or carfilzomib-based. The remaining 4 relapse/refractory patients were not on active anti-myeloma therapy due to advance disease stage (hospice) or other more pressing comorbidities. Information on treatment status was missing for two patients, these were both classified as newly diagnosed multiple myeloma.([Table 2](#T2){ref-type="table"}) Overall, a total of 39 patients had undergone high-dose melphalan followed by autologous stem cell transplant; 7 patients within the 12 months prior to contracting COVID-19. Two patients had a prior allogeneic stem cell transplant several years before the COVID-19 diagnosis. ([Table 2](#T2){ref-type="table"}) Forty-two patients (42%) had hypogammaglobulinemia (IgG \<650 mg/dL) and 18 patients (18%) had severe hypogammaglobulinemia (IgG \<400 mg/dL).

The laboratory findings in this multiple myeloma cohort revealed lymphopenia and elevated C-reactive protein, ferritin, D-dimer, and IL-6 levels. ([Table 3](#T3){ref-type="table"}) Patients who met the adverse combined endpoint (i.e. ICU-admission, mechanical ventilation, or death) had overall higher levels of inflammatory markers reflecting a more severe infection and cytokine activation.

Of the 100 patients with multiple myeloma and a SARS-CoV-2 positive RNA PCR test on this study, 74 (74%) were admitted due to COVID-19; 16 were admitted to the ICU and 13 of these patients were placed on mechanical ventilation. Regarding treatments used for COVID-19, 52 patients were treated with hydroxychloroquine and 52 with azithromycin, 42 had the combination of the two and 35 received neither hydroxychloroquine nor azithromycin. ([Table 4](#T4){ref-type="table"}) Nine patients received treatment with IL-6 inhibitors, tocilixumab or sarilumab, and one patient was treated with the IL-1 inhibitor anakinra and the TNF-alpha inhibitor infliximab. Other treatments included high dose steroids, broad-spectrum antibiotics, and investigational anti-viral therapies such as lopinavir-ritonavir and remdesivir. Two patients were treated with convalescent plasma. Eighteen of the multiple myeloma patients, thus 24% of those admitted, expired during the follow-up time.

Twenty-seven patients (27%) of the 100 multiple myeloma patients met the combined adverse end-point (ICU-admission, mechanical ventilation, or death) and the risk was highest for patients with hypertension. None of the studied risk factors were significantly associated (P\>0.05) with adverse outcomes, including hypertension, OR 2.3 (95% CI 0.9--5.9); diabetes, OR 1.1 (95% CI 0.3--3.2); age \>65 years, OR 2.0 (95% CI 0.8--5.3), or male gender, OR 0.9 (95% CI 0.4--2.1). Based on small numbers (N=7), patients who received high-dose melphalan chemotherapy followed with autologous stem cell transplant within 12 months prior to COVID-19 diagnosis were not significantly associated with the adverse combined endpoint, OR 1.2 (95% CI 0.2--7.4). Also, we did not observe any statistical association between the adverse combined endpoint and hypogammaglobulinemia (IgG \<650 mg/dL); OR 0.9 (95% CI 0.3--2.5) or severe hypogammaglobulinemia (IgG \<400 mg/dL); and 1.2 (95% CI 0.4--4.2), respectively. ([Table 5](#T5){ref-type="table"})

In the entire case series of 127 patients with plasma cell disorders, the OR of severe outcome (ICU-admission, mechanical ventilation, or death) was significantly elevated for those with hypertension (OR 3.4, 95% 1.5--8.1) while diabetes, male gender, age \>65 years, or chronic obstructive pulmonary disease/asthma were not significantly associated with the adverse combined end-point.

Discussion {#S13}
==========

COVID-19 is a disease caused by the SARS-CoV-2 virus where, in the general population, the most severe outcomes are observed among elderly patients and patients with cardiovascular comorbidities.^[@R3],[@R13]^ There is limited data on outcomes in patients with cancers particularly patients with hematological malignancies. Here, we present the first large case series of COVID-19 in patients with multiple myeloma, a plasma cell malignancy associated with a compromised immune system, due to both disease biology and anti-myeloma therapies. Consecutive patients with multiple myeloma and related precursor diseases with confirmed presence of SARS-CoV-2 between March 1^st^ and April 30^th^, 2020 from five large academic centers in New York City were included in this study. In the general population, the probability of dying from COVID-19 has been reported to be between 0.5--3% including all COVID-19 positive patients, and between 6--30% for hospitalized patients due to the virus.^[@R1],[@R3],[@R13]--[@R16]^ Here, we show that among 74 multiple myeloma patients admitted due to COVID-19, the mortality rate was 24% which thus is in the higher range of what has been reported in the general population.

We were motivated to better understand risk factors associated with severe outcomes from COVID-19 positive multiple myeloma patients. Specifically, we studied host characteristics as well as available variables related to the disease and treatment. Similar to reports from the general population, we found more men than women diagnosed with COVID-19 in this series, and there was a tendency towards a higher OR for adverse outcome (ICU-admission, mechanical ventilation, or death) in patients with hypertension. In the analysis of the entire series of COVID-19 positive patients with multiple myeloma and related plasma cell disorders (N=127), similar to the general population, cardiovascular risk factors were significantly associated with adverse outcome.^[@R3]^ Independent of COVID-19, typically, patients with multiple myeloma are at an increased risk of infections due to both disease and treatment associated immunosuppression.^[@R17]^ Examples of these associations are the immunomodulatory and conventional chemotherapy drugs which cause myelosuppression, the targeted monoclonal antibodies such as anti-CD-38 associated with suppression of the humoral immune system.^[@R18]--[@R22]^ In the current series, we did not identify an association between hypogammaglobulinemia and adverse outcome; however, due to the lack of detailed biomarker data, we were unable to rule out associations involving other immunological mechanisms (such as T-cell suppression) that are important in the immune response towards viral and other infections. In multiple myeloma patients undergoing high-dose melphalan chemotherapy followed by autologous stem cell transplant, it is well-known that there are severe acute as well as sustained long-term immunosuppression including broad aspects of the immune system.^[@R23],[@R24]^ In this study, 39 of the 100 multiple myeloma patients included had been treated with autologous stem cell transplant, 7 within the 12 months prior to contracting SARS-CoV-2. Based on small numbers (N=7), the OR for the adverse combined end-point was not significantly elevated in patients who had high-dose melphalan chemotherapy followed by autologous stem cell transplant within 12 months prior to contracting COVID-19. Despite not seeing an increased mortality associated with high-dose melphalan chemotherapy followed by autologous stem cell transplant, we note the concerns of the American Society of Hematology as well as the International Myeloma Society whose recommendations state that for transplant-eligible patients, high-dose melphalan chemotherapy followed with autologous stem cell transplant should be postponed, if possible, until the pandemic abates.^[@R25],[@R26]^ Given that it is unknown whether there could be additional seasonal outbreaks in upcoming winter of 2020 as well as following years, it is good clinical practice to have this discussion with every patient. When a safe and efficacious SARS-CoV-2 vaccine becomes available, it should be recommended to multiple myeloma patients and should be added to re-immunization programs for melphalan-induced inactivation of prior vaccines.

To minimize the risk for exposure, management of multiple myeloma including the use of infusions, injections and oral drugs has been adjusted to favor fewer visits, fewer injections/infusions and a preference for oral drugs.^[@R25]--[@R31]^ All five academic centers limited the use of high-dose melphalan and autologous stem cell transplant and only a few high risk patients have been transplanted during the outbreak. Additionally, in our experience, patients with multiple myeloma have been particularly adherent to the general recommendations for social distancing.^[@R32],[@R33]^ This may have contributed to the relatively low number of patients with multiple myeloma and COVID-19 in this cohort given the population of New York City (8.4 million), the overall number of confirmed cases (\>200,000), and the large catchment area covered by the five included hospital centers.

In prior reports from the general population, the immune response in patients with severe COVID-19 show a unique pattern with high IL-6, low HLA-DR expression, and dysregulation of lymphocytes characterized by CD4 lymphopenia and subsequently B-cell lymphopenia.^[@R34]^ In the current series of multiple myeloma patients, we found high levels of IL-6, elevated ferritin, and low absolute lymphocyte levels. Furthermore, previous studies have reported that COVID-19 infection can lead to a hypercoagulable state and patients with severe COVID-19 have an increased risk of venous thromboembolism and stroke.^[@R4],[@R35]^ In this series, D-dimer levels were found to be elevated and one patient had a cerebrovascular event leading to significant neurological sequelae. The biological underpinnings of these observations remain to be further explained in functional studies.

No treatment has so far shown an unequivocal beneficial effect for treatment of COVID-19. Hydroxychloroquine in combination with azithromycin was initially suggested to be an effective treatment combination; however, validation trials have been unable to confirm beneficial effects. Importantly, the World Health Organization recently expressed concern over cardiac arrhythmias and other potentially serious effects with the hydroxychloroquine-azithromycin combination and several of the initial publications have now been retracted.^[@R36]--[@R39]^ A few patients in our series were treated with lopinavir-ritonavir; however, clinical trials have not shown a clinical benefit of these anti-retroviral drugs.^[@R40]^ Recent reports on remdesivir as well as treatment with convalescent plasma therapy have showed promising results and there are case reports on successful treatment of COVID-19 with IL-6 blockade.^[@R41]--[@R46]^ Additionally, there are indications that the Bruton tyrosine kinase inhibitor acalabrutinib can reduce the excessive inflammatory response in patients with severe COVID-19.^[@R47]^

Limitations of this study includes it being a case-series from tertiary cancer centers with a selected patient population in which patients who were treated at local hospitals in the outpatient setting were less likely to be included. There was missing data for certain laboratory results for some of the patients, primarily those who were treated as outpatients where not all tested for C-reactive protein, ferritin, D-dimer, or IL-6 levels.

In summary, we present data on a large case-series of COVID-19 positive patients with multiple myeloma and related precursor diseases showing case fatality rates in the higher range of reports from the general population. We comprehensively investigated the role of other comorbidities and found that the strongest risk factors for severe outcome were similar to those in the general population. The molecular and immunological mechanisms responsible for this finding remain unclear; however, given that patients with multiple myeloma are at an increased risk of various other infections due to both disease and treatment associated immunosuppression^[@R17]^, current recommendation by American Society of Hematology and the International Myeloma Society state that high-dose melphalan chemotherapy followed with autologous stem cell transplant should be postponed, if possible, until the pandemic levels off.^[@R25],[@R26]^ Ongoing larger studies with a wide range of hematological malignancies will provide additional information on geographical variations of risk factors in these patients. Going forward, until there is a vaccine or effective treatment for COVID-19, clinical management and treatment of patients with multiple myeloma have to be carefully considered and adjusted to reduce the risk of exposure and minimize immune-suppression, while still aiming to achieve deep remissions in the era of COVID-19.
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###### 

Patients' characteristics

                                                           Number (%)
  -------------------------------------------------------- ------------
  **All patients**                                         127 (100)
  **Men**                                                  68 (54)
  **Women**                                                59 (46)
  **Median age at COVID-19 (years)**                       68 years
  **Former/Current smoker**                                34 (27)
  **Never smoker**                                         92 (73)
  **Multiple myeloma**                                     100 (79)
   **Newly diagnosed multiple myeloma**                    30
   **Stable multiple myeloma without relapse**             35
   **Relapse/refractory multiple myeloma**                 35
  **Monoclonal gammopathy of undetermined significance**   20 (16)
  **Smoldering multiple myeloma**                          3 (2.4)
  **AL amyloidosis**                                       3 (2.4)
  **Solitary plasmacytoma**                                1 (0.8)

Three multiple myeloma patients had concomitant AL amyloidosis.

###### 

Treatment regimens in patients with multiple myeloma at the time of COVID-19 diagnosis

                                                          Number
  ------------------------------------------------------- --------
  **All patients**                                        100
  **Patients with ongoing treatment**                     86
   **Bortezomib-including regimen**                       20
   **Carfilzomib-including regimen**                      15
   **Daratumumab-including regimen**                      24
   **Ixazomib-including regimen**                         6
   **Lenalidomide maintenance**                           22
   **Other treatments**[\*](#TFN3){ref-type="table-fn"}   10
   **Prior MEL/ASCT**                                     39
   **Prior allogeneic transplant**                        2
  **Not on treatment**                                    12
  **Missing information regarding treatment status**      2

MEL/ASC=high dose melphalan and autologous stem cell transplantation

Other treatments included DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin), low dose melphalan, panabinostat, iberomid, chlarithromycin, venetoclax, selinexor, and AMG-701.

###### 

Laboratory findings in patients with multiple myeloma and COVID-19

                                   All patients   With combined adverse outcome   Without combined adverse outcome   NA/ND (N)                         
  -------------------------------- -------------- ------------------------------- ---------------------------------- ------------ -------- ----------- ----
                                   Median         Range                           Median                             Range        Median   Range       
  **ANC (x10^9^/L)**               3.4            0.4--17.5                       3.6                                0.6--17.2    2.7      0.4--17.5   18
  **ALC (x10^9^/L)**               0.7            0.1--3.6                        0.6                                0.1--1.2     0.6      0.1--1.8    18
  **Platelets (x10^9^/L)**         162            6--507                          112                                6--310       166      19--507     18
  **IgG level (mg/dL)**            732            155--5319                       668                                318--3779    678      155--4783   13
  **C-reactive protein (mg/dL)**   49             2.7--350                        45                                 9.2--292     22.3     2.7--259    35
  **Ferritin (ng/mL)**             652            2--40 000                       2015                               58--40,000   502      2--7174     36
  **D-dimer (mcg/mL FEU)**         1.3            0.13--83                        3.5                                0.3--83      1.1      0.2--5.5    41
  **Interleukin-6 (pg/dL)**        57             3.7--3238                       68.5                               7.3--3238    74       6.0--532    50

Adverse combined end-point=ICU-admission, mechanical ventilation, or death

ANC=Absolute neutrophil count, ALC=absolute lymphocyte count, NA=Not available, ND=Not done

###### 

Treatment administered for COVID-19 in patients with multiple myeloma

  Treatment for COVID19                                  Number
  ------------------------------------------------------ --------
  **Total number of patients**                           100
  **Patient receiving therapy for COVID-19**             65
   **Hydroxychloroquine**                                52
   **Azithromycin**                                      52
   **Combination hydroxychloroquine and azithromycin**   40
   **IL-6 blockade**                                     9
   **Lopinavir-ritonavir**                               4
   **Remdisivir**                                        1

###### 

Odds ratios (ORs) of the combined adverse end-point (intensive care unit admission, mechanical ventilation, or death).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         Multiple myeloma and patients (N=100) OR (95% CI)   Multiple myeloma and related plasma cell disorders (N=127) OR (95% CI)
  -------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------
  **Any cardiovascular disease**         1.3 (0.5--3.8)                                      1.6 (0.6--4.2)

  **Hypertension**                       2.3 (0.9--5.9)                                      3.5 (1.5--8.1)

  **Diabetes**                           1.1 (0.3--3.3)                                      0.8 (0.3--2.4)

  **COPD/asthma**                        2.8 (0.2--45.9)                                     4.3 (0.98--19.2)

  **Male gender**                        0.9 (0.4--2.1)                                      0.7 (0.3--1.5)

  **Age \>65 years**                     2.0 (0.8--5.3)                                      1.8 (0.8--4.1)

  **MEL/ASCT**\                          1.2 (0.2--7.4)                                      NA
  **\<12m vs \>12m prior to COVID-19**                                                       

  **IgG \<650 mg/dL**                    1.2 (0.4--3.1)                                      NA

  **IgG \<400 mg/dL**                    1.2 (0.4--4.2)                                      NA
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

COPD=chronic obstructive pulmonary disorder

MEL/ASCT=high dose melphalan and autologous stem cell transplantation

IgG=Immunoglobulin G level
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